Transplantation potential of hematopoietic cells released into the circulation during routine chemotherapy for non-Hodgkin's lymphoma.
dc.contributor.author | Pettengell, Ruth | |
dc.contributor.author | Testa, Nydia G | |
dc.contributor.author | Swindell, Ric | |
dc.contributor.author | Crowther, Derek | |
dc.contributor.author | Dexter, T Michael | |
dc.date.accessioned | 2010-05-27T15:13:39Z | |
dc.date.available | 2010-05-27T15:13:39Z | |
dc.date.issued | 1993-10-01 | |
dc.identifier.citation | Transplantation potential of hematopoietic cells released into the circulation during routine chemotherapy for non-Hodgkin's lymphoma. 1993, 82 (7):2239-48 Blood | en |
dc.identifier.issn | 0006-4971 | |
dc.identifier.pmid | 7691253 | |
dc.identifier.uri | http://hdl.handle.net/10541/99946 | |
dc.description.abstract | Primitive hematopoietic cells released into the peripheral blood (PB) were studied in 50 patients with high-grade non-Hodgkin's lymphoma enrolled in a phase III trial of intensive weekly chemotherapy (VAPEC-B) alone or with granulocyte colony-stimulating factor (G-CSF). Mononuclear cells numbers were monitored and their in vitro growth potential assessed in clonogenic progenitor cell assays and in long-term culture. Total colony-forming cells (granulocyte-macrophage [GM], burst-forming unit, erythroid [BFU-E], Mix-CFC) were increased 40-fold (median) over baseline with chemotherapy alone and 106-fold with chemotherapy and G-CSF after the final dose. CD34+ cells were increased to a median of 4%, equivalent to that in normal bone marrow (BM) controls. Circulating colony-forming cell levels were maximal when the recovering total white blood cell (WBC) count reached 5 to 10 x 10(9)/L. The timing of the maximum was reproducible in individual patients. Therefore the WBC count can be used as a guide to the timing of leukapheresis. PB cells from normal controls' and patients' prechemotherapy were unable to sustain hemopoiesis in two-stage long-term cultures. In contrast, PB cells collected from patients primed with chemotherapy alone or chemotherapy with G-CSF at the time of predicted maximal colony-forming cell release were able to generate and sustain hematopoiesis in long-term cultures at a level comparable or superior to normal BM. These findings indicate that the use of G-CSF after routine outpatient chemotherapy stimulates maximal release of primitive hemopoietic cells into the circulation, including colony-forming cells and long-term culture-initiating cells. Their numbers are comparable with those in normal BM and are such that a single leukapheresis will usually yield enough cells for hemopoietic reconstitution after myeloablative chemotherapy. | |
dc.language.iso | en | en |
dc.subject | Haematopoietic Stem Cells | en |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols | |
dc.subject.mesh | Bleomycin | |
dc.subject.mesh | Bone Marrow | |
dc.subject.mesh | Bone Marrow Cells | |
dc.subject.mesh | Cells, Cultured | |
dc.subject.mesh | Colony-Forming Units Assay | |
dc.subject.mesh | Cyclophosphamide | |
dc.subject.mesh | Doxorubicin | |
dc.subject.mesh | Etoposide | |
dc.subject.mesh | Granulocyte Colony-Stimulating Factor | |
dc.subject.mesh | Hematopoietic Stem Cells | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Leukocyte Count | |
dc.subject.mesh | Lymphoma, Non-Hodgkin | |
dc.subject.mesh | Monocytes | |
dc.subject.mesh | Recombinant Proteins | |
dc.subject.mesh | Time Factors | |
dc.subject.mesh | Vincristine | |
dc.title | Transplantation potential of hematopoietic cells released into the circulation during routine chemotherapy for non-Hodgkin's lymphoma. | en |
dc.type | Article | en |
dc.contributor.department | Department of Experimental Haematology, Paterson Institute for Cancer Research and Christie Hospital, Manchester, UK. | en |
dc.identifier.journal | Blood | en |
html.description.abstract | Primitive hematopoietic cells released into the peripheral blood (PB) were studied in 50 patients with high-grade non-Hodgkin's lymphoma enrolled in a phase III trial of intensive weekly chemotherapy (VAPEC-B) alone or with granulocyte colony-stimulating factor (G-CSF). Mononuclear cells numbers were monitored and their in vitro growth potential assessed in clonogenic progenitor cell assays and in long-term culture. Total colony-forming cells (granulocyte-macrophage [GM], burst-forming unit, erythroid [BFU-E], Mix-CFC) were increased 40-fold (median) over baseline with chemotherapy alone and 106-fold with chemotherapy and G-CSF after the final dose. CD34+ cells were increased to a median of 4%, equivalent to that in normal bone marrow (BM) controls. Circulating colony-forming cell levels were maximal when the recovering total white blood cell (WBC) count reached 5 to 10 x 10(9)/L. The timing of the maximum was reproducible in individual patients. Therefore the WBC count can be used as a guide to the timing of leukapheresis. PB cells from normal controls' and patients' prechemotherapy were unable to sustain hemopoiesis in two-stage long-term cultures. In contrast, PB cells collected from patients primed with chemotherapy alone or chemotherapy with G-CSF at the time of predicted maximal colony-forming cell release were able to generate and sustain hematopoiesis in long-term cultures at a level comparable or superior to normal BM. These findings indicate that the use of G-CSF after routine outpatient chemotherapy stimulates maximal release of primitive hemopoietic cells into the circulation, including colony-forming cells and long-term culture-initiating cells. Their numbers are comparable with those in normal BM and are such that a single leukapheresis will usually yield enough cells for hemopoietic reconstitution after myeloablative chemotherapy. |